User profiles for Ian C Marschner
 | Ian MarschnerProfessor of Biostatistics, University of Sydney Verified email at sydney.edu.au Cited by 8097 |
Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction …
RJ Simes, IC Marschner, D Hunt, D Colquhoun… - Circulation, 2002 - Am Heart Assoc
Background— The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial
showed that pravastatin significantly reduced mortality and coronary heart disease (CHD) …
showed that pravastatin significantly reduced mortality and coronary heart disease (CHD) …
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
IC Marschner, AC Collier, RW Coombs… - Journal of Infectious …, 1998 - academic.oup.com
Data from 1330 human immunodeficiency virus type 1 (HIV-1)-infected patients enrolled in
seven antiretroviral treatment trials were analyzed to characterize the clinical benefit of …
seven antiretroviral treatment trials were analyzed to characterize the clinical benefit of …
[HTML][HTML] Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
DV Havlir, IC Marschner, MS Hirsch… - … England Journal of …, 1998 - Mass Medical Soc
Background Combination antiretroviral therapy with indinavir, zidovudine, and lamivudine
can suppress the level of human immunodeficiency virus (HIV) RNA in plasma below the …
can suppress the level of human immunodeficiency virus (HIV) RNA in plasma below the …
[HTML][HTML] Estimating age-specific COVID-19 fatality risk and time to death by comparing population diagnosis and death patterns: Australian data
IC Marschner - BMC medical research methodology, 2021 - Springer
Background Mortality is a key component of the natural history of COVID-19 infection.
Surveillance data on COVID-19 deaths and case diagnoses are widely available in the public …
Surveillance data on COVID-19 deaths and case diagnoses are widely available in the public …
[HTML][HTML] Biosimilarity and interchangeability: principles and evidence: a systematic review
…, M Cook, W Liauw, M Marabani, IC Marschner… - BioDrugs, 2018 - Springer
Background The efficacy, safety and immunogenicity risk of switching between an originator
biologic and a biosimilar or from one biosimilar to another are of potential concern. …
biologic and a biosimilar or from one biosimilar to another are of potential concern. …
Long-term risk stratification for survivors of acute coronary syndromes: results from the long-term intervention with pravastatin in ischemic disease (LIPID) study
IC Marschner, D Colquhoun, RJ Simes… - Journal of the American …, 2001 - jacc.org
OBJECTIVES We developed a prognostic strategy for quantifying the long-term risk of
coronary heart disease (CHD) events in survivors of acute coronary syndromes (ACS). …
coronary heart disease (CHD) events in survivors of acute coronary syndromes (ACS). …
Relative risk regression: reliable and flexible methods for log-binomial models
IC Marschner, AC Gillett - Biostatistics, 2012 - academic.oup.com
Relative risks (RRs) are generally considered preferable to odds ratios in prospective studies.
However, unlike logistic regression for odds ratios, the standard log-binomial model for …
However, unlike logistic regression for odds ratios, the standard log-binomial model for …
A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic …
Background In the setting of metastatic colorectal cancer (CRC), anti-EGFR antibodies are
not currently recommended for individuals with KRAS mutant tumours. This is based on …
not currently recommended for individuals with KRAS mutant tumours. This is based on …
A randomized trial of nafamostat for Covid-19
…, JSY Lau, R Littleford, JA Marsh, IC Marschner… - NEJM …, 2023 - evidence.nejm.org
Background Nafamostat mesylate is a potent in vitro antiviral agent that inhibits the host
transmembrane protease serine 2 enzyme used by severe acute respiratory syndrome …
transmembrane protease serine 2 enzyme used by severe acute respiratory syndrome …
Changes in lipoprotein‐associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long …
…, S Blankenberg, EH Barnes, IC Marschner… - Journal of the …, 2013 - Am Heart Assoc
Background Lipoprotein‐associated phospholipase A2 (Lp‐ PLA 2 ) levels are associated
with coronary heart disease ( CHD ) in healthy individuals and in patients who have had …
with coronary heart disease ( CHD ) in healthy individuals and in patients who have had …